No headlines found.
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Business Wire (Mon, 1-Jun 8:00 AM ET)
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
Business Wire (Thu, 28-May 9:00 AM ET)
Biote Reports First Quarter 2026 Financial Results
Business Wire (Wed, 6-May 4:05 PM ET)
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
Business Wire (Wed, 22-Apr 4:05 PM ET)
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Biote Corp. - Class A trades on the NASDAQ stock market under the symbol BTMD.
As of June 17, 2026, BTMD stock price climbed to $2.29 with 82,203 million shares trading.
BTMD has a beta of 2.09, meaning it tends to be more sensitive to market movements. BTMD has a correlation of 0.12 to the broad based SPY ETF.
BTMD has a market cap of $69.46 million. This is considered a Micro Cap stock.
Last quarter Biote Corp. - Class A reported $45 million in Revenue and $.06 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.02.
In the last 3 years, BTMD traded as high as $8.44 and as low as $1.27.
The top ETF exchange traded funds that BTMD belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFMC.
BTMD has underperformed the market in the last year with a return of -42.5%, while SPY returned +25.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BTMD shares. However, BTMD has outperformed the market in the last 3 month and 2 week periods, returning +65.3% and +6.5%, while SPY returned +12.5% and -1.2%, respectively. This indicates BTMD has been having a stronger performance recently.
BTMD support price is $2.08 and resistance is $2.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTMD shares will trade within this expected range on the day.
